Debate Over Biomarker Test Reimbursement

A private company advising the agency that oversees Medicare has recommended against reimbursing for biomarker tests, a decision that has raised concerns among cancer specialists.

In July 2026, Gretchen Morgenson reported on the issue, highlighting a significant moment for LeeAnne Loney in the summer of 2024.

Biomarker tests are crucial for tailoring cancer treatments to individual patients. They help oncologists determine the most effective therapies. The recommendation against reimbursement risks limiting access to these vital tests.

Experts in the medical field argue that denying reimbursement could hinder advancements in cancer treatment. Physicians emphasize the importance of these tests in developing personalized treatment plans.

“Biomarker tests are a game changer for oncology,” commented a cancer specialist. “They allow us to treat our patients more effectively.”

Despite the recommendation, many in the medical community continue to advocate for the availability of biomarker tests. They stress the need for policies that support innovation in cancer treatment.